Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results

Gossamer Bio, Inc. (NASDAQ:GOSS) on Tuesday reported mixed third-quarter financial results.

Gossamer Bio reported quarterly losses of $(7.36) per share which missed the analyst consensus estimate of $(3.68) per share. The company reported quarterly sales of $38.431 million which beat the analyst consensus estimate of $12.148 million.

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH,” said Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”

Gossamer Bio shares fell 4.7% to trade at $10.75 on Wednesday.

These analysts made changes to their price targets on Gossamer Bio following earnings announcement.

• Wedbush analyst Laura Chico maintained the stock with a Neutral and lowered the price target from $80 to $32.
• Piper Sandler analyst Yasmeen Rahimi maintained the stock with an Overweight rating and lowered the price target from $120 to $96.

Considering buying GOSS stock? Here’s what analysts think:

Photo via Shutterstock